ClinicalTrials.gg
TerminatedNCT06282861ANTES B+Updated Aug 14, 2025

ANTES B+ Clinical Trial

A Phase 4 interventional study of Trelegy Ellipta 100/62.5/25Mcg Inh 30D and Brimica in Chronic Obstructive Pulmonary Disease, sponsored by Fundacio Privada Mon Clinic Barcelona. Terminated at 1 site in Spain. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Fundacio Privada Mon Clinic Barcelona · Phase 4, Interventional, and Prevention

How we know

Why this study was terminated
Delays in the opening and activation of participating sites, and a low recruitment rate, with only 48 participants enrolled over the course of one year

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain — 42 open to participants now, 45 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Spain.

Enrollment
204th of 238
48 · median 336
Started
2024
with 11 others
Phase 4
40 of 309
5 open now
Registered
275th of 309
by date

Among the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, this one is the 204th largest by enrollment of the 238 interventional ones that give a count, is one of 12 that started in 2024, is one of 40 in phase 4, and was the 275th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

42 of the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, or all of them as a file.
02

Study summary

Current guidelines recommend initial treatment with dual long-acting bronchodilator therapy (LABA-LAMA) in patients with Chronic Obstructive Pulmonary Disease (COPD) of group B (defined by CAT≥10 and none or 1 moderate exacerbation). However, the investigators hypothesize that there is a subgroup of B patients (B+) at a particularly high risk for poor clinical control, characterized by the following:

  • 1 moderate exacerbation in the previous year
  • CAT≥10 despite current treatment with LABA -LAMA
  • Blood eosinophil levels of ≥150 cells/ml

the investigators further hypothesize that B+ patients could benefit from triple therapy treatment (LABA-LAMA + Inhaled Corticosteroids). Therefore, the main goal of this clinical trial is to compare the efficacy of Trelegy (triple therapy) in improving clinical control in GOLD B+ patients with chronic obstructive disease when compared to standard double therapy (LABA -LAMA).

The clinical control is a validated composite endpoint that includes two domains, the patient's stability, and the impact of the disease.

1028 patients will be randomly allocated to receive either the standard therapy or Trelegy and will be monitored by the investigators for 1 year in 2 on-site visits + 2 remote visits.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
  • ECOPD
  • eosinophil
  • Trelegy
  • Clinical Control
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male
  • 40-80 yrs. of age
  • Current/former smokers ≥10 pack-year
  • Diagnosis of according to GOLD 2023 (post-bronchodilator(BD) /FVC\<0.7 in the appropriate clinical context) with FEV1 post-BD 30-70% of the reference value
  • B+ phenotype

    • CAT≥10 despite being on LABA-LAMA for ≥3 months, and
    • 1 moderate ECOPD in the previous year (treated with a short course of oral and/or antibiotics), and
    • ≥150 blood Eos/ μL (as determined by a single Eos measurement in the previous 12 months available in the medical record of the patient)
  • A signed and dated written prior to study participation.

Exclusion criteria

Exclusion Criteria:

  • GOLD E (≥2 moderate or 1 severe ECOPD in the previous year)
  • ICS treatment (or oral for whatever reason) during the last 8 weeks (10)
  • ECOPD during the last 8 weeks
  • Current diagnosis of asthma or documented history of asthma in the medical record of the patient according to the 2023 Global Initiative for Asthma (GINA) guidelines or other accepted guidelines
  • Other concomitant respiratory disease (e.g., bronchiectasis, lung fibrosis, lung neoplasm)
  • Use of domiciliary long-term oxygen therapy or non-invasive ventilation
  • Alpha-1 antitrypsin deficiency
  • Unstable or life-threatening cardiac disease, including:

    • Myocardial infarction or unstable angina in the last 6 months
    • Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 3 months.
    • (NYHA) Class IV Heart failure.
  • Participation on Pulmonary Rehabilitation Program within 4 weeks prior to Screening or subjects who plan to enter the acute phase of a Pulmonary Rehabilitation Program during the study.
  • Long term antibiotic therapy (antibiotics are allowed for the short-term treatment of an exacerbation or for short term treatment of other acute infections during the study).
  • Systemic, oral, parenteral corticosteroids used for and/or other diseases in the 8 weeks before entering in the study (oral/systemic corticosteroids may be used to treat COPD exacerbations during the study).
  • Active neoplasm
  • \< 1 yr.
  • Current participation in other RCTs (randomized clinical trial)
  • Non-compliance: subjects at risk of non-compliance, or unable to comply with the study procedures.
  • Any disease, disability, or geographic location that would limit compliance for scheduled visits.
  • Known allergy to Trelegy® components (vilanterol, umeclidinium and/or fluticasone furoate) or inability to use the Ellipta® device.
  • Women who are pregnant or lactating or are planning to become pregnant during the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Trelegy

    Trelegy commercial product. 1 inhalation daily for 12 months

    Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30D

  • Active comparator
    LABA-LAMA

    Any LABA-LAMA combination approved in Spain is accepted. To be used according to product specifications for 12 months.

    Drug: Brimica · Drug: Duaklir · Drug: Ultibro · Drug: Ulunar · Drug: Xoterna · Drug: Anoro · Drug: Laventair · Drug: Spiolto Respimat · Drug: Yanimo · Drug: Foradil · Drug: Broncoral · Drug: Formoterol stada · Drug: Oxis · Drug: Formatris · Drug: Formoterol Aldo · Drug: Onbrez · Drug: Oslif · Drug: Hirobriz · Drug: Striverdi · Drug: Beglan · Drug: Betamican · Drug: Inaspir · Drug: Serevent · Drug: Soltel · Drug: Eklira · Drug: Bretaris · Drug: Seebri · Drug: Tovanor · Drug: Enurev · Drug: Spiriva · Drug: Tavulus · Drug: Sirkava · Drug: Braltus · Drug: Gregal · Drug: Incruse · Drug: Rolufta

Interventions

  • DrugTrelegy Ellipta 100/62.5/25Mcg Inh 30D

    Product to be used according to specifications. 1 inhalation daily for 12 months

    Also known as: LABA/LAMA/ICS

  • DrugBrimica

    As per product specifications

    Also known as: LABA/LAMA

  • DrugDuaklir

    As per product specifications

    Also known as: LABA/LAMA

  • DrugUltibro

    As per product specifications

    Also known as: LABA/LAMA

  • DrugUlunar

    As per product specifications

    Also known as: LABA/LAMA

  • DrugXoterna

    As per product specifications

    Also known as: LABA/LAMA

  • DrugAnoro

    As per product specifications

    Also known as: LABA/LAMA

  • DrugLaventair

    As per product specifications

    Also known as: LABA/LAMA

  • DrugTiotropium-olodaterolStudies of Tiotropium-olodaterolTiotropium-olodaterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LABA/LAMA

  • DrugYanimo

    As per product specifications

    Also known as: LABA/LAMA

  • DrugFormoterolStudies of FormoterolFormoterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LABA

  • DrugBroncoral

    As per product specifications

    Also known as: LABA

  • DrugFormoterol stada

    As per product specifications

    Also known as: LABA

  • DrugFormoterolStudies of FormoterolFormoterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LABA

  • DrugFormatris

    As per product specifications

    Also known as: LABA

  • DrugFormoterol Aldo

    As per product specifications

    Also known as: LABA

  • DrugIndacaterolStudies of IndacaterolIndacaterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LABA

  • DrugOslif

    As per product specifications

    Also known as: LABA

  • DrugIndacaterol maleateStudies of Indacaterol maleateIndacaterol maleate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LABA

  • DrugOlodaterolStudies of OlodaterolOlodaterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LABA

  • DrugBeglan

    As per product specifications

    Also known as: LABA

  • DrugBetamican

    As per product specifications

    Also known as: LABA

  • DrugInaspir

    As per product specifications

    Also known as: LABA

  • DrugSalmeterol XinafoateStudies of Salmeterol XinafoateSalmeterol Xinafoate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LABA

  • DrugSoltel

    As per product specifications

    Also known as: LABA

  • DrugAclidinium bromideStudies of Aclidinium bromideAclidinium bromide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LAMA

  • DrugAclidinium bromideStudies of Aclidinium bromideAclidinium bromide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LAMA

  • DrugGlycopyrrolateStudies of GlycopyrrolateGlycopyrrolate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LAMA

  • DrugTovanor

    As per product specifications

    Also known as: LAMA

  • DrugEnurev

    As per product specifications

    Also known as: LAMA

  • DrugTiotropiumStudies of TiotropiumTiotropium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LAMA

  • DrugTavulus

    As per product specifications

    Also known as: LAMA

  • DrugSirkava

    As per product specifications

    Also known as: LAMA

  • DrugBraltus

    As per product specifications

    Also known as: LAMA

  • DrugGregal

    As per product specifications

    Also known as: LAMA

  • DrugUmeclidinium bromideStudies of Umeclidinium bromideUmeclidinium bromide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product specifications

    Also known as: LAMA

  • DrugRolufta

    As per product specifications

    Also known as: LAMA

06

What researchers measure

Primary outcomes

  1. Clinical Control (CC)

    Patient persistently controlled by CC at all study visits (a subject to be categorized as having clinical control they must meet the criteria at month 3, 6, 9 and 12).

    Time frame: 3,6,9 and 12 months

Secondary outcomes

  1. Clinical Important Deterioration (CID)

    Patients persistently non deteriorated by CID-CAT at all study visits.(a subject to be categorized as having control by CID-CAT they must meet the criteria a month 3, 6, 9 and 12).

    Time frame: 3,6,9 and 12 months

  2. Patients persistently controlled

    Patients persistently controlled (at all visits) throughout the study between the two study arms as per: * CC - Stability Domain 1. General status since the last visit 2. Exacerbations in the last 3 months * CC - Impact Domain 1. Sputum color 2. Rescue medication use 3. Minutes walked per day 4. Dyspnea (mMRC) * CID-CAT - Exacerbations * CID-CAT - (Patient reported outcomes)PROs * CID-CAT - Lung function

    Time frame: 3,6,9 and 12 months

  3. Time to deterioration

    time to first event of not being CC or suffer CID-CAT

    Time frame: 3,6,9 and 12 months

  4. Time to no control event of CC - Stability Domain

    Time to first no control event for CC - Stability Domain

    Time frame: 3,6,9 and 12 months

  5. Time to no control event of CC - Impact Domain

    Time to first no control event for CC - Impact Domain

    Time frame: 3,6,9 and 12 months

  6. Time to deterioration event of CID-CAT Exacerbations

    Time to deterioration event for CID-CAT Exacerbations

    Time frame: 3,6,9 and 12 months

  7. Time to deterioration event of CID-CAT Spirometry

    Time to deterioration event for CID-CAT Spirometry

    Time frame: 3,6,9 and 12 months

  8. Exacerbation rate

    To compare several Health status related endpoints between study arms including: d.To evaluate the mean and annual rate of: * Moderate exacerbations (ECOPD) * Severe ECOPD (hospitalized) * Moderate and Severe ECOPD

    Time frame: 3,6,9 and 12 months

  9. Time to first Exacerbation

    To compare several Health status related endpoints between study arms including: e.To evaluate time to first ECOPD including: * Moderate ECOPD * Severe ECOPD (hospitalized) * Moderate or Severe ECOPD

    Time frame: 3,6,9 and 12 months

  10. Spirometry changes

    To compare several Health status related endpoints between study arms including: f. To assess annual FEV1(Forced Expiratory volume) and FVC (forced vital capacity) changes (ml/year)

    Time frame: 3,6,9 and 12 months

  11. Independent predictors

    Independent predictors with a potential negative impact on achieving the CC, each of its domains and each of its variables at each study visit.

    Time frame: 3,6,9 and 12 months

07

Study locations

1 site
  • Hospital Clínic Barcelona
    Barcelona, Catalonia 08036, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jan 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2024
First posted
Feb 28, 2024
StartActual
Feb 29, 2024
Primary completionActual
Jan 23, 2025
CompletionActual
Jan 23, 2025
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06282861
Lead sponsor
Fundacio Privada Mon Clinic Barcelona
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Feb 29, 2024
Primary completion
Jan 23, 2025
Completion
Jan 23, 2025
Last update
Aug 14, 2025

Study contacts

Àlvar Agustí
principal investigator · Hospital Clinic of Barcelona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion